



PRESS RELEASE

AMOÉBA and VISCUS BIOLOGICS announce a joint program for the treatment of multi-resistant bacteria for human wound care

Lyon, Cleveland, June 27th, 2017 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water, announced today the development of a collaboration with VISCUS BIOLOGICS in order to carry out collective testing on a new wound care application in the field of human health.

VISCUS BIOLOGICS has a proven expertise in the field of wound care products, in particular collagen-based dressings, and has already carried out a large number of projects with commercial partners and research centers in the US and Europe.

Following preliminary *in vitro* testing, the two companies intend to extend their cooperation and further confirm, through additional *in vitro* and *in vivo* testing, **the action of the *Willaertia magna C2c Maky* micro-organism against certain pathogenic Multi-Drug Resistant (MDR) bacteria that resist multiple antibiotics.** *Willaertia magna C2c Maky* could therefore be used with advanced wound care dressings. This project is in the first instance focusing on the US market.

There is a strong demand in the wound care market to develop innovative solutions to manage bacterial resistance to antibiotics as alternatives to commercially available antimicrobial dressings.

In a global advanced wound care market estimated at USD 17 billion¹, the antimicrobial dressing segment represents USD 1.87 billion² with a potential CAGR of USD 841 million³ in the USA.

« With this project with AMOEBA, VISCUS BIOLOGICS is aiming to address a very important market segment in the wound care industry. Willaertia Magna C2c Maky is a natural predator of bacteria, including pathogenic bacteria. The amoeba can function as a phagocyte that envelops and dissolves the bacteria internally while being biocompatible to the surrounding cells and tissue. The Willaertia Magna C2c Maky amoeba is also effective against biofilms of bacteria, acting to break down the biofilm. For these reasons, we are studying the effectiveness on clinically relevant pathogens.

*Ultimately, Willaertia magna C2c Maky on its own or in combination with other treatments may provide another tool for treating wounds that are infected or at risk of becoming infected. » stated **Peter GINGRAS, CEO of VISCUS BIOLOGICS.***

*« With this collaboration with VISCUS BIOLOGICS, AMOEBA is reaching an historical turning point in its development. We will be able to contribute to the advancement of clinical research to meet the global challenge of bacterial resistance to antibiotics (chemical molecules). Preliminary in vitro testing supports the use of Willaertia Magna C2c Maky on antibiotic-resistant strains. This partnership opens new development perspectives for AMOEBA beyond water treatment, in the chronic wound care market. » added **Fabrice PLASSON, CEO of AMOEBA.***

About VISCUS BIOLOGICS:

Viscus Biologics, LLC designs, manufactures and delivers innovative medical devices with the objective of positively impacting the health and well-being of patients around the world. It provides biologic extracellular matrix components and devices to partners under an original design manufacturing business model. Novel wound care, orthopedic, cardiovascular, and general surgery products are in the pipeline based upon allograft or xenograft tissue. The company's headquarters are based in Cleveland (Ohio, USA). Additionally, our close relationship with our sister company Aran Biomedical offers partners an integrated approach to the development of products that combine biologics with synthetic materials. More information on www.viscusbiologics.com.



About AMOEBA:

AMOEBAs objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn(4) AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn(5). Similarly, in a global wound care market estimated at EUR 15.2bn(1), AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million(3). The use of Willaertia magna C2c Maky in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on www.amoeba-biocide.com.



(1) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

(2) M. Diligence, "Wound Management: An \$18.5 billion+ worldwide market in 2021," MedMarket Diligence, 10 June 2013. [Online]. Available: <http://blog.mediligence.com/2013/06/10/wound-management-an-18-5-billion-worldwide-market-in-2021/>. [Accessed 14 February 2017].

(3) BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017.

(4) : Sources combinées par Amoéba venant des traiteurs d'eau, de Freedonia, d'Eurostat et MarketsandMarkets

(5) : Données Amoéba combinées à partir des sources : DRIRE 2013, Eurostat, ARHIA 2013

Contacts:

Amoéba

Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
[ggasparetto@actifin.fr](mailto:gasparetto@actifin.fr)

Viscus Biologics

Peter Gingras
President & CEO
Tel. : +1 (0)216-744-2740
peter.gingras@viscusbiologics.com